Journal
BIOMARKERS
Volume 16, Issue -, Pages S42-S50Publisher
INFORMA HEALTHCARE
DOI: 10.3109/1354750X.2011.578754
Keywords
Kidney transplantation; Gene marker; T cell; B cell; HLA antibodies; Elispot
Categories
Ask authors/readers for more resources
To avoid toxic side effects caused by permanent immunosuppressive treatment, research in transplantation focuses on new treatment strategies inducing tolerance or allowing drug weaning. Implementing drug minimization into clinical routine can be only safely achieved when guided by biomarkers reflecting the individual immune reactivity. We review recently described biomarkers and assays allowing identification of patients suitable for drug weaning or at risk of rejection. However, the majority of described biomarkers and assays have not been validated in prospective clinical trials. Thus, collaborative efforts are needed to design and perform prospective multicenter trials to validate the identified biomarkers across different laboratories.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available